RAS
Royalty Pharma Commits $2 Billion to Revolution Medicines for RAS Cancer Drug Development
Royalty Pharma; Revolution Medicines; daraxonrasib; $2 billion funding; RAS cancer; synthetic royalty; secured debt; clinical development; oncology; biotech funding
Cardiff Oncology’s Onvansertib Shows Promising Results in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial
Cardiff Oncology, Onvansertib, RAS-mutated metastatic colorectal cancer, Phase 2 CRDF-004 trial, objective response rate (ORR), first-line treatment.